Zevra Therapeutics’ MIPLYFFA receives FDA approval as first treatment for Niemann-Pick disease

Pallavi Madhiraju- September 20, 2024

Zevra Therapeutics Inc. has announced U.S. Food and Drug Administration (FDA) approval of MIPLYFFA (arimoclomol), a capsule-based treatment for Niemann-Pick disease type C (NPC), a ... Read More

Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges

Pallavi Madhiraju- September 20, 2024

Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted Fast Track Designation by the United States ... Read More

Terns Pharmaceuticals faces market pressure following stock offering announcement

Pallavi Madhiraju- September 11, 2024

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing small-molecule product candidates for serious diseases such as oncology and obesity, has seen a significant decline in ... Read More